PT-141 (Bremelanotide): What the Evidence Actually Shows

PT-141 is bremelanotide, a melanocortin-receptor agonist that acts on the brain’s sexual-desire pathways. Unlike most peptides sold online, this one is real medicine: bremelanotide is FDA-approved as Vyleesi, a single-dose autoinjector approved in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women^[1]. The catch is that the “PT-141” sold as a grey-market “research peptide” — often used off-label by men for libido or erectile function — is the same molecule stripped of the FDA-regulated manufacturing, identity testing, and dosing that make Vyleesi a verified product. This article reviews what the human evidence actually shows: the RECONNECT Phase 3 trials behind Vyleesi’s approval, how bremelanotide works (a central melanocortin mechanism, not a vascular one), its real side-effect profile (nausea in about 40% of patients, transient blood-pressure rises, focal skin darkening), and the gap between legitimate Vyleesi and the unverified “PT-141” vial. One thing up front: bremelanotide is not a weight-loss drug, and we are not going to pretend otherwise.

The honest summary

• It is genuinely FDA-approved — for sexual desire, not weight. Bremelanotide is approved as Vyleesi (2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women^[1]. It is a real, regulated drug listed in DailyMed.
• It works on the brain, not blood vessels. Bremelanotide is a melanocortin-receptor agonist that acts centrally on the neural circuits governing sexual desire^[6] — a different mechanism from PDE5 inhibitors like sildenafil, which work on blood flow.
• The Phase 3 evidence is modest but real. The two identical RECONNECT trials (1,267 women randomized) met their co-primary endpoints for desire and distress versus placebo, with small effect sizes (P<.001 integrated)^[1][3].
• Side effects are common. Nausea occurred in about 40% of patients; the drug also causes transient blood-pressure increases with a small drop in heart rate, and focal hyperpigmentation (skin darkening) in roughly 1%^[2][4][5].
• “PT-141” research peptide is NOT Vyleesi. The grey-market version sold for “research use only” is the same molecule without verified identity, purity, sterility, or dose. Off-label use in men has no FDA approval and rests on far thinner evidence.
• This is not a weight-loss treatment. Bremelanotide is not approved for, studied for, or mechanistically aimed at fat loss. If a seller pitches PT-141 for weight loss, that claim has no evidence behind it.

What PT-141 / bremelanotide actually is

PT-141 is the research-era code name for bremelanotide, a synthetic cyclic peptide and analog of α-melanocyte-stimulating hormone (α-MSH). It is an agonist at melanocortin receptors — particularly the MC4 receptor in the central nervous system — which is how it influences sexual desire from the brain rather than by acting on the genital vasculature^[6]. Developed by Palatin Technologies, it was approved by the FDA in 2019 under the brand name Vyleesi and is now marketed by Cosette Pharmaceuticals. The approved product is a single-dose autoinjector delivering 1.75 mg subcutaneously into the abdomen or thigh, taken on an as-needed basis at least 45 minutes before anticipated sexual activity^[1]. That “as-needed, before activity” design is unusual for a desire drug and reflects its central, relatively short-acting mechanism.

The FDA-approved evidence: the RECONNECT Phase 3 trials

Vyleesi’s approval rests on two identical Phase 3, randomized, double-blind, placebo-controlled trials known collectively as RECONNECT (studies 301 and 302), reported by Kingsberg and colleagues in Obstetrics & Gynecology in 2019^[1]. Of 1,267 premenopausal women with acquired, generalized HSDD who were randomized, roughly 1,200–1,250 made up the safety and efficacy populations. The co-primary endpoints were the change in the Female Sexual Function Index desire-domain score and the change in a Female Sexual Distress Scale item measuring distress about low desire. Bremelanotide beat placebo on both: the integrated increase in desire score was 0.35 and the integrated reduction in distress was −0.33, each statistically significant (P<.001)^[1].

Those are real, replicated, placebo-controlled results — but the effect sizes are modest, and it is worth being honest about that. A separate long-term analysis confirmed efficacy and characterized safety over extended use^[2], and prespecified subgroup analyses across the RECONNECT program supported the consistency of the effect^[3]. A 2025 review of HSDD pharmacotherapy places bremelanotide among the small number of evidence-backed options for premenopausal HSDD while noting its tolerability limitations^[7]. This is a drug that works for some women on a specific, narrowly defined desire disorder — not a libido cure-all, and certainly not a metabolic drug.

Side effects and safety

Bremelanotide’s tolerability is its biggest practical limitation. Per the FDA label and the pooled clinical-development safety analysis, nausea is the most common adverse reaction, reported in about 40% of treated patients; it required anti-nausea medication in roughly 13% and led about 8% to stop the drug^[4]. Flushing and headache are also common^[1]. The peptide transiently raises blood pressure and lowers heart rate after each dose — on the order of a few mmHg systolic with a small drop in heart rate, typically resolving within about 12 hours — which is why it is not recommended for people with uncontrolled hypertension or known cardiovascular disease^[5]. Finally, because it is a melanocortin agonist, it can cause focal hyperpigmentation (darkening of skin or gums), reported in about 1% of patients and more likely with repeated or daily dosing and in people with darker skin; resolution after stopping was not confirmed in all cases^[4].

Legit Vyleesi vs grey-market “PT-141” research peptide

Here is the distinction that matters most. Vyleesi is bremelanotide as an FDA-approved, prescription autoinjector: a verified molecule, a known 1.75 mg dose, sterile manufacturing, a written label, and a defined indication in premenopausal women. “PT-141” sold online as a “research peptide” is the same chemical name, but the product in the vial has not been verified by any agency for identity, purity, sterility, or dose. It is typically labeled “for research use only, not for human consumption” — a disclaimer routinely ignored by buyers, many of them men using it off-label for libido or erectile complaints, a use that bremelanotide is not FDA-approved for and that rests on much weaker evidence than the female-HSDD data.

Is PT-141 a weight-loss peptide? No.

Because PT-141 sometimes appears on the same vendor menus as fat-loss peptides, it occasionally gets lumped in with “weight-loss peptides.” That is a category error. Bremelanotide is a melanocortin agonist aimed at sexual desire; it has no FDA-approved or evidence-backed role in appetite, satiety, or fat metabolism, and no human trial has tested it as a weight-loss treatment. The broader melanocortin system is studied in metabolic research^[6], but that is distinct from any claim that injecting bremelanotide makes people lose weight — a claim that has no clinical support. If weight loss is your goal, this is the wrong molecule. For a map of which peptides actually have weight-loss evidence (and which do not), see our hub review of peptides for weight loss and the forthcoming peptides A-to-Z evidence guide.

Bottom line

PT-141 is bremelanotide — and unlike most peptides we review, it is real, FDA-approved medicine. As Vyleesi, it has two replicated Phase 3 trials behind a narrow approval: acquired, generalized HSDD in premenopausal women, with modest but genuine effects on desire and distress^[1][3]. It also has meaningful downsides — nausea in roughly 40% of users, transient blood-pressure rises, and occasional skin darkening^[4][5] — which is why it is dose-limited and prescription-controlled. The grey-market “PT-141” sold as a research peptide is the same molecule without any of those safeguards, and its popular off-label use in men is not FDA-approved. What it is not, under any version, is a weight-loss drug. If you are considering it for sexual desire, do it through a licensed prescriber with the approved product; if you are considering it for weight loss, look elsewhere entirely.

This article is educational and is not medical advice. Bremelanotide’s FDA-approved status, indication, dosage form, and adverse-reaction rates were verified against the current DailyMed Vyleesi label before publication; every PMID was verified live against the PubMed database. Citations 1 through 5 and 7 are human clinical trials, safety analyses, and pharmacotherapy reviews of bremelanotide; citation 6 is a mechanism review of the central melanocortin system. Discuss any prescription treatment with a licensed clinician.